VWF清除与FVIII结合的遗传决定因素影响儿童血友病A患者FVIII药代动力学
研究纳入43例儿童血友病A患者,探讨影响FVIII药代动力学的遗传决定因素。发现VWF:Ag及VWFpp/VWF:Ag与FVIII半衰期相关,VWFpp/VWF:Ag在非O血型患者中与FVIII半衰期负相关,O型患者无相关。VWF的FVIII结合活性与FVIII半衰期正相关,VWF、CLEC4M和STAB2位点常见变异与FVIII药代动力学相关。
要点
- VWF:Ag和VWFpp/VWF:Ag与儿童血友病A患者FVIII半衰期相关。
- VWFpp/VWF:Ag仅于非O血型患者与FVIII半衰期负相关,O型患者无相关。
- VWF、CLEC4M和STAB2位点常见变异与FVIII药代动力学相关。
核心结论
- VWF清除和ABO糖基化修饰FVIII药代动力学的机制基础在儿童血友病A群体中得到描述。
- 本研究首次在儿童血友病A患者中识别出非VWF和非ABO的变异可修饰FVIII药代动力学。
研究设计与样本
- 研究纳入43例儿童血友病A患者,分析遗传决定因素对FVIII药代动力学特征的影响。
主要发现
- VWF:Ag和VWFpp/VWF:Ag与FVIII半衰期相关,而VWFpp与FVIII半衰期不相关。
- VWFpp/VWF:Ag在非O血型患者中与FVIII半衰期负相关,O型患者中无相关性。
- VWF的FVIII结合活性与FVIII半衰期正相关。
- 在VWF:FVIIIB降低而VWF:Ag未降低的患者中,识别出罕见或低频非同义VWF变异p.(Arg826Lys)和p.(Arg852Glu)。
- VWF、CLEC4M和STAB2位点的常见变异与FVIII药代动力学特征相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Factor VIII (FVIII) pharmacokinetic (PK) properties show high interpatient variability in hemophilia A patients. Although previous studies have determined that age, body mass index, von Willebrand factor antigen (VWF:Ag) levels, and ABO blood group status can influence FVIII PK, they do not account for all observed variability. In this study, we aim to describe the genetic determinants that modify the FVIII PK profile in a population of 43 pediatric hemophilia A patients. We observed that VWF:Ag and VWF propeptide (VWFpp)/VWF:Ag, but not VWFpp, were associated with FVIII half-life. VWFpp/VWF:Ag negatively correlated with FVIII half-life in patients with non-O blood type, but no correlation was observed for type O patients, suggesting that von Willebrand factor (VWF) half-life, as modified by the ABO blood group, is a strong regulator of FVIII PK. The FVIII-binding activity of VWF positively correlated with FVIII half-life, and the rare or low-frequency nonsynonymous VWF variants p.(Arg826Lys) and p.(Arg852Glu) were identified in patients with reduced VWF:FVIIIB but not VWF:Ag. Common variants at the VWF, CLEC4M, and STAB2 loci, which have been previously associated with plasma levels of VWF and FVIII, were associated with the FVIII PK profile. Together, these studies characterize the mechanistic basis by which VWF clearance and ABO glycosylation modify FVIII PK in a pediatric population. Moreover, this study is the first to identify non-VWF and non-ABO variants that modify FVIII PK in pediatric hemophilia A patients.
引用
- Swystun LL, Ogiwara K, Rawley O, et al. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients. Blood. 2019. PMID: 31350267. doi:10.1182/blood.2019000190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。